Impaired insulin-mediated vasorelaxation in a nonobese model of type 2 diabetes: Role of endothelin-1

Canadian Journal of Physiology and Pharmacology

Volumn 86, Issue 6, 2008, Pages 358-364

  Elgebaly, Mostafa M ^a   Kelly, Aisha ^b   Harris, Alex K ^a   Elewa, Hazem ^a   Portik Dobos, Vera ^b   Ketsawatsomkron, Pimonrat ^b   Marrero, Mario ^b   Ergul, Adviye ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Endothelin 1; Type II diabetes; Vascular insulin resistance

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MOLECULAR MARKER; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PROTEIN KINASE B BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; GOTO KAKIZAKI RAT; HYPERINSULINEMIA; IMMUNOBLOTTING; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC PARAMETERS; MYOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; THORACIC AORTA; VASODILATATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; AORTA, THORACIC; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; GLUCOSE CLAMP TECHNIQUE; INSULIN; MALE; PHOSPHORYLATION; RATS; RATS, WISTAR; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; VASODILATION;

EID: 44949239600     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-034     Document Type: Conference Paper

References (30)

1. Ahlborg, G., Shemyakin, A., Bohm, F., Gonon, A., and Pernow, J. 2007. Dual endofhelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care, 30: 591-596. doi:10.2337/dc06-1978. PMID:17327326.
2. Balsiger, B., Rickenbacher, A., Boden, P.J., Biecker, E., Tsui, J., Dashwood, M., et al. 2002. Endothelin A-receptor blockade in experimental diabetes improves glucose balance and gastrointestinal function. Clin. Sci. (Lond.), 103(Suppl 48): 430S-433S. PMID:12193138.
3. Battistini, B., Berthiaume, N., Kelland, N.F., Webb, D.J., and Kohan, D.E. 2006. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp. Biol. Med. (Maywood), 231: 653-695. PMID:16740981.
4. Berthiaume, N., Carlson, C.J., Rondinone, C.M., and Zinker, B.A. 2005a. Endothelin antagonism improves hepatic insulin sensitivity associated with insuhn signaling in Zucker fatty rats. Metabolism, 54: 1515-1523. doi:10.1016/j.metabol.2005.05.019. PMID:1653642.
5. Berthiaume, N., Wessale, J.L., Opgenorth, T.J., and Zinker, B.A. 2005b. Metabolic responses with endothelin antagonism in a model of insulin resistance. Metabolism, 54: 735-740. doi:10.1016/j.metabol.2004. 12.019. PMID:15931607.
6. Biddinger, S.B., and Kahn, C.R. 2006. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68:123-158. doi:10.1146/annurev.physiol.68.040104.124723. PMID:16460269.
7. Chen, S., Mukherjee, S., Chakraborty, C. and Chakrabarti, S. 2003. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am. J. Physiol. Cell Physiol. 284: C263-C272. PMID:12388107.
8. Cheng, Z.J., Vaskonen, T., Tikkanen, I., Nurminen, K., Ruskoaho, H., Vapaatalo, H., et al. 2001. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension, 37: 433-439. PMID:11230314.
9. Elgebaly, M.M., Portik-Dobos, V., Sachidanandam, K., Rychly, D., Malcom, D., Johnson, M.H., and Ergul, A. 2007. Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes. Vasc. Pharmacol. 47: 125-130. doi:10.1016/j.vph.2007.05.006.
10. Ergul, A., Schultz Johansen, J., Stromhaug, C., Harris, A.K., Hutchinson, J., Tawfik, A., et al. 2004. Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: role of endothelin-1. J. Pharmacol. Exp. Ther. 313: 70-77. doi:10.1124/jpet.104.078105. PMID:15608082.
11. Farese, R.V., Standaert, M.L., Yamada, K., Huang, L.C., Zhang, C., Cooper, D.R., et al. 1994. Insulin-induced activation of glycerol-3-phosphate acyltransferase by a chiro-inositol-containing insulin mediator is defective in adipocytes of insulin-resistant, type II diabetic, Goto-Kakizaki rats. Proc. Natl. Acad. Sci. U.S.A. 91: 11040-11044. doi:10.1073/pnas.91.23.11040. PMID:7972005.
12. Ferri, C., Belhni, C., Desideri, G., Di Francesco, L., Baldoncini, R., Santucci, A., and De Mattia, G. 1995. Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes, 44: 431-436. doi:10.2337/diabetes.44.4.431. PMID:7698512.
13. Fukuda, C., Khan, Z.A., Barbin, Y.P., Farhangkhoee, H., Tilton, R.G., and Chakrabarti, S. 2005. Endothelin-mediated remodeling in aortas of diabetic rats. Diabetes Metab. Res. Rev. 21: 367-375. doi:10.1002/dmrr.527. PMID:15580650.
14. Haak, T., Jungmann, E., Felber, A., Hillmann, U., and Usadel, K.H. 1992. Increased plasma levels of endothehn in diabetic patients with hypertension. Am. J. Hypertens. 5: 161-166. PMID:1575942.
15. Harris, A.K., Hutchinson, J.R., Sachidanandam, K., Johnson, M.H., Dorrance, A.M., Stepp, D.W., et al. 2005. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes, 54: 2638-2644. doi:10.2337/diabetes.54.9.2638. PMID:16123352.
16. Hotamisligil, G.S. 2006. Inflammation and metabolic disorders. Nature, 444: 860-867. doi:10.1038/nature05485. PMID:17167474.
17. Ishibashi, K.I., Imamura, T., Sharma, P.M., Huang, J., Ugi, S., and Olefsky, J.M. 2001. Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes. J. Clin. Invest. 107: 1193-1202. doi:10.1172/JCI11753. PMID:11342583.
18. Janssen, U., Vassihadou, A., Riley, S.G., Phillips, A.O., and Floege, J. 2004. The quest for a model of type II diabetes with nephropathy: the Goto Kakizaki rat. J. Nephrol. 17: 769-773. PMID:15593049.
19. Jiang, Z.Y., Lin, Y.W., Clemont, A., Feener, E.P., Hein, K.D., Igarashi, M., et al. 1999. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J. Clin. Invest. 104: 447-457. doi:10.1172/JCI5971. PMID:10449437.
20. Khan, Z.A., and Chakrabarti, S. 2003. Endothelins in chronic diabetic comphcations. Can. J. Physiol. Pharmacol. 81: 622-634. doi:10.1139/y03-053. PMID:12839273.
21. Lteif, A., Vaishnava, P., Baron, A.D., and Mather, K.J. 2007. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes, 56: 728-734. doi:10.2337/db06-1406. PMID:17327443.
22. Miller, A.W., Tulbert, C., Puskar, M., and Busija, D.W. 2002. Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance. Hypertension, 40: 78-82. doi:10.1161/01.HYP.0000022806.87281.62. PMID:12105142.
23. Ottosson-Seeberger, A., Lundberg, J.M., Alvestrand, A., and Ahlborg, G. 1997. Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiol. Scand. 161: 211-220. doi:10.1046/j.1365-201X.1997. 00212.x. PMID:9366964.
24. Sachidanandam, K., Harris, A., Hutchinson, J., and Ergul, A. 2006. Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Exp. Biol. Med. (Maywood), 231: 1016-1021. PMID:16741041.
25. Saltiel, A.R., and Kahn, C.R. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 414: 799-806. doi:10.1038/414799a. PMID:11742412.
26. Song, W., and Ergul, A. 2006. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: Relation to vessel size. Cardiovasc. Diabetol. 5: 3. doi:10.1186/1475-2840-5-3. PMID:16503991.
27. Standaert, M.L., Sajan, M.P., Miura, A., Kanoh, Y., Chen, H.C., Farese, R.V., Jr., and Farese, R.V. 2004. Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver. Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high fat-induced insulin-resistant states. J. Biol. Chem. 279: 24929-24934. doi:10.1074/jbc.M402440200. PMID:15069067.
28. Takahashi, K., Ghatei, M.A., Lam, H.C., O'Halloran, D.J., and Bloom, S.R. 1990. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia, 33: 306-310. doi:10.1007/BF00403325. PMID:2198188.
29. White, M.F. 2003. Insulin signaling in health and disease. Science, 302: 1710-1711. doi:10.1126/science.1092952. PMID:14657487.
30. Wilkes, J.J., Hevener, A., and Olefsky, J. 2003. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes, 52: 1904-1909. doi:10.2337/diabetes.52.8.1904. PMID:12882904.